Evogene and Pure Capital Group Reach Cooperation Agreement to Resolve Differences and Reconstitute Board of Directors
Key Highlights
- ➤Evogene (EVGN) reaches cooperation agreement with Pure Capital Group, resolving outstanding differences
- ➤Pure Capital Group will withdraw its special tender-offer notice and observe a 60-day standstill
- ➤Four Pure Capital nominees are expected to join Evogene’s seven-member reconstituted board
- ➤Shareholder meeting must occur within 42 days to approve agreement and director appointments
- ➤Evogene will halt share and convertible-security issuance during the 60-day standstill, except ordinary employee issuances
Evogene and Pure Capital Group Reach Cooperation Agreement to Resolve Differences and Reconstitute Board of Directors PR Newswire
REHOVOT, Israel, Oct. 6, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneer in computational chemistry specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today announced that it has entered into a comprehensive cooperation agreement (the "Agreement") with L.I.A. Pure Capital Ltd. and Invest Pro Shukai Hon Ltd. (together, the "Pure Capital Group") to resolve all outstanding differences between the parties. The agreement is intended to establish long-term operational stability and empower Evogene to focus entirely on its goal of becoming a world leader in AI-driven small-molecule discovery and optimization for the pharmaceutical and ag-chemical industries.
Get started
Create a free account to read the full story.